Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines

[1]  F. Bosch,et al.  Repurposing dasatinib for diffuse large B cell lymphoma , 2019, Proceedings of the National Academy of Sciences.

[2]  Jun Lu,et al.  Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma. , 2018, Blood.

[3]  J. Utikal,et al.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression , 2018, Front. Immunol..

[4]  Christian Templin,et al.  40 Years on , 2017, European heart journal.

[5]  Jun O. Liu,et al.  Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation , 2017, Journal of Virology.

[6]  Z. Yao,et al.  LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required , 2017, Oncogene.

[7]  Juan F. García,et al.  Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS) , 2017, Histopathology.

[8]  S. Tangye,et al.  Human immunity against EBV—lessons from the clinic , 2017, The Journal of experimental medicine.

[9]  E. Miao,et al.  Programmed cell death as a defence against infection , 2017, Nature Reviews Immunology.

[10]  Vijaya Subramaniam,et al.  Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3. , 2017, Virology.

[11]  Z. Estrov,et al.  Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia , 2016, The Journal of Immunology.

[12]  Samuel J. Taylor,et al.  The targeting of human and mouse B lymphocytes by dasatinib. , 2015, Experimental hematology.

[13]  A. Grañena,et al.  CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival , 2015, The Journal of pathology.

[14]  Xenia Geeraerts,et al.  Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies , 2014, Front. Oncol..

[15]  K. Ando,et al.  Clinical outcome of Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era , 2014, Cancer science.

[16]  S. Nimmagadda,et al.  The intricate role of CXCR4 in cancer. , 2014, Advances in cancer research.

[17]  Junying Yuan,et al.  Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death , 2013, Nature Reviews Molecular Cell Biology.

[18]  Ling Wang,et al.  Interferon Regulatory Factor 4 Is Activated through c-Src-Mediated Tyrosine Phosphorylation in Virus-Transformed Cells , 2013, Journal of Virology.

[19]  D. Rowe,et al.  The Effect of Epstein-Barr Virus Latent Membrane Protein 2 Expression on the Kinetics of Early B Cell Infection , 2013, PloS one.

[20]  L. Gordon,et al.  Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. , 2012, Antiviral research.

[21]  J. Huh,et al.  Impact of the Epstein–Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea , 2012, Annals of Hematology.

[22]  J. Kutok,et al.  Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model , 2012, Cell.

[23]  M. Rowe,et al.  Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations , 2011, Herpesviridae.

[24]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[25]  K. Bieging,et al.  Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis , 2009, Proceedings of the National Academy of Sciences.

[26]  E. Vellenga,et al.  Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  N. Carragher,et al.  Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 , 2009, Molecular oncology.

[28]  R. Longnecker,et al.  Epstein–Barr virus LMP2A accelerates MYC-induced lymphomagenesis , 2009, Oncogene.

[29]  B. Cookson,et al.  Pyroptosis: host cell death and inflammation , 2009, Nature Reviews Microbiology.

[30]  R. Longnecker,et al.  Epstein-Barr Virus Latent Membrane Protein 2A Preferentially Signals through the Src Family Kinase Lyn , 2008, Journal of Virology.

[31]  A. Beech,et al.  Classification and Treatment , 2008 .

[32]  A. Carbone,et al.  EBV-associated lymphoproliferative disorders: classification and treatment. , 2008, The oncologist.

[33]  P. De Baetselier,et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.

[34]  L. Honigberg,et al.  Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.

[35]  L. Otterbein,et al.  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.

[36]  G. M. Taylor,et al.  Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. , 2005, Blood.

[37]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[38]  L. Young,et al.  Epstein–Barr virus: 40 years on , 2004, Nature Reviews Cancer.

[39]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[40]  R. Longnecker,et al.  LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways. , 2001, Virology.

[41]  D. Thorley-Lawson,et al.  EBV Persistence Involves Strict Selection of Latently Infected B Cells1 , 2000, The Journal of Immunology.

[42]  R. Longnecker,et al.  Epstein-Barr Virus LMP2A-Induced B-Cell Survival in Two Unique Classes of EμLMP2A Transgenic Mice , 2000, Journal of Virology.

[43]  R. Longnecker,et al.  Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. , 2000, Journal of virology.

[44]  B. Kempkes,et al.  The Proto-Oncogene c-myc Is a Direct Target Gene of Epstein-Barr Virus Nuclear Antigen 2 , 1999, Journal of Virology.

[45]  R. Alon,et al.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.

[46]  V. Godfrey,et al.  Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[48]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[49]  D. Thorley-Lawson,et al.  Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell , 1997 .

[50]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[51]  G. Miller,et al.  Recovery of Epstein-Barr virus from nonproducer neonatal human lymphoid cell transformants. , 1979, Virology.